Wave Life Sciences WVE GB — Income Tax Reconciliation Tax Credits Research

Similar metrics at other companies

IOSPGB — Effective Income Tax Rate Reconciliation Innovation Incentives Amount

-$800K0.0%

HXLGB — Effective Income Tax Rate Reconciliation Tax Incentives Amount

$625K-3.8%

IONSIncome Tax Reconciliation Tax Credits Research

$4.44M—

RBCIncome Tax Reconciliation Tax Credits Research

$600K-4.0%

IOSPGB — Effective Income Tax Rate Reconciliation Innovation Incentives Percent

-0.6%-0.2pp

HXLGB — Effective Income Tax Rate Reconciliation Tax Incentives Percent

-0.5%+0.1pp

Other financials

Income statement

See full

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

See full

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

See full

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

See full

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Profitability

See full

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

See full

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.

The official record: Wave Life Sciences’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's gb — income tax reconciliation tax credits research.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Wave Life Sciences's GB — income tax reconciliation tax credits research?: Wave Life Sciences (WVE) reported GB — income tax reconciliation tax credits research of -$459K in Q4 2025.
What does GB — income tax reconciliation tax credits research mean?: This metric reflects the reduction in income tax expense attributable to research and development tax credits claimed in specific geographic jurisdictions. It serves as a proxy for the company's investment in innovation and the extent to which government incentives subsidize R&D activities. Higher values indicate a greater utilization of tax-based R&D incentives.